TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07169175: A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Sponsor: SineuGene Therapeutics Co., Ltd. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 21 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,181,925

Rescue Site Savings

+$787,950

Unlock Full NCT07169175 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07169175 Rescue Dossier →